NKTR

$37.76+2.19%visit website

NEKTAR THERAPEUTICS

Market Cap

$1.3B

Live price × SEC shares (Aug 7, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.40

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

23.6

TTM to Jun 2026 · revenue

P/B

1.4

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	11,790	21,807	10,861	10,131	54,589
Cost of revenue	0.00	0.00
Research & development	27,252	29,712	35,680	39,129	131,773
Operating income	(31,672)	(27,665)	(39,054)	(42,341)	(140,732)
Pretax income	(35,021)	(34,702)	(43,090)	(40,301)	(153,114)
Income tax	(33.0)	31.0	64.0	2.0	64.0
Net income	(35,522)	(36,079)	(44,904)	(40,622)	(157,127)
EPS (basic) ($)	(1.87)		(1.82)	(1.23)	—
EPS (diluted) ($)	(1.87)		(1.82)	(1.23)	—
Weighted avg. shares (basic)	18,947		24,736	33,055
Weighted avg. shares (diluted)	18,947		24,736	33,055

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 62 more quarters, back to Mar 2010, with Tormere Pro.

Corporate Events (8-K)

19 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 1, 2026 accepted 11:57 AM ET	7.01Reg FD disclosure	Document SEC ↗
Sep 25, 2026 accepted 11:00 AM ET	8.01Other events	Document SEC ↗
Sep 8, 2026 accepted 8:10 PM ET	7.01Reg FD disclosure	Document SEC ↗
Aug 13, 2026 accepted 8:25 PM ET	2.02Earnings release	Document SEC ↗
Jun 5, 2026 accepted 8:30 PM ET	5.07Shareholder vote	Document SEC ↗
May 8, 2026 accepted 9:11 PM ET	1.01Material agreement5.02Officer / director change	Document SEC ↗
May 7, 2026 accepted 8:30 PM ET	2.02Earnings release	Document SEC ↗
Apr 23, 2026 accepted 10:06 AM ET	1.01Material agreement8.01Other events	Document SEC ↗
Apr 20, 2026 accepted 8:58 PM ET	7.01Reg FD disclosure	Document SEC ↗
Apr 20, 2026 accepted 12:02 PM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

53%

W/W +2.2pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

0.13x

Avg Daily Selling (90d)

6.7 sh/day

Baseline Daily Selling

133 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-18	2026-08-20	ROBIN HOWARD W	Director & President & CEO	Sale	418	$71.98	$30K	54.6K	View
2026-08-18	2026-08-20	Zalevsky Jonathan	Chief R&D Officer	Sale	186	$71.98	$13K	9,570	View
2026-06-30	2026-07-02	Zalevsky Jonathan	Chief R&D Officer	Sale	5,681	$70.00	$398K	9,756	View
2026-06-17	2026-06-18	ROBIN HOWARD W	Director & President & CEO	Sale	10.0K	$61.19	$612K	55.0K	View
2026-06-16	2026-06-18	ROBIN HOWARD W	Director & President & CEO	Sale	10.0K	$60.32	$603K	65.0K	View

1–5 of 10

1 / 2

Recent News

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Stocktwits · 2026-11-04

Nektar Therapeutics: Focus Returns To The Strengths Of The Company

SeekingAlpha · 2026-10-30

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Yahoo · 2026-10-29

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

Yahoo · 2026-10-27

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo · 2026-10-23

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

Yahoo · 2026-10-15

Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case

Yahoo · 2026-10-12

UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

Benzinga · 2026-10-12

Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

Benzinga · 2026-10-12

UBS initiates Nektar Therapeutics stock at Neutral on catalyst timing

Investing.com · 2026-10-12

BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

Benzinga · 2026-10-09

Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

Benzinga · 2026-10-09

Cedar Grove Capital Q3 2026 Portfolio Update

SeekingAlpha · 2026-10-07

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Yahoo · 2026-10-07

EADV26: Key late-stage readouts from the conference

Yahoo Finance · 2026-10-05

Informational purposes only, not investment advice.

NKTR

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

NEKTAR THERAPEUTICS (NKTR)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-08-18	ROBIN HOWARD W	S	418	$30,087.64
2026-08-18	Zalevsky Jonathan	S	186	$13,388.28
2026-06-30	Zalevsky Jonathan	S	5,681	$397,670
2026-06-17	ROBIN HOWARD W	S	5,500	$334,455
2026-06-17	ROBIN HOWARD W	S	4,500	$277,425